1
|
Robotically assisted vs laparoscopic hysterectomy among women with benign gynecologic disease.
|
JAMA
|
2013
|
4.67
|
2
|
Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.
|
J Clin Oncol
|
2010
|
3.33
|
3
|
Comparative effectiveness of robotic versus laparoscopic hysterectomy for endometrial cancer.
|
J Clin Oncol
|
2012
|
2.59
|
4
|
Resource utilization for ovarian cancer patients at the end of life: how much is too much?
|
Gynecol Oncol
|
2005
|
2.26
|
5
|
Latest research and treatment of advanced-stage epithelial ovarian cancer.
|
Nat Rev Clin Oncol
|
2013
|
2.24
|
6
|
Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions.
|
Gynecol Oncol
|
2007
|
2.20
|
7
|
Lymphadenectomy influences the utilization of adjuvant radiation treatment for endometrial cancer.
|
Am J Obstet Gynecol
|
2011
|
2.19
|
8
|
Racial disparities for uterine corpus tumors: changes in clinical characteristics and treatment over time.
|
Cancer
|
2009
|
2.15
|
9
|
Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply?
|
Gynecol Oncol
|
2004
|
2.08
|
10
|
Nationwide trends in the performance of inpatient hysterectomy in the United States.
|
Obstet Gynecol
|
2013
|
2.05
|
11
|
Prognostic significance of adenocarcinoma histology in women with cervical cancer.
|
Gynecol Oncol
|
2012
|
1.98
|
12
|
Comparative performance of the 2009 international Federation of gynecology and obstetrics' staging system for uterine corpus cancer.
|
Obstet Gynecol
|
2010
|
1.98
|
13
|
Predictors of massive blood loss in women with placenta accreta.
|
Am J Obstet Gynecol
|
2011
|
1.86
|
14
|
Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers.
|
Proc Natl Acad Sci U S A
|
2003
|
1.83
|
15
|
Primary therapy for early-stage cervical cancer: radical hysterectomy vs radiation.
|
Am J Obstet Gynecol
|
2009
|
1.75
|
16
|
Trends in hospital volume and patterns of referral for women with gynecologic cancers.
|
Obstet Gynecol
|
2013
|
1.72
|
17
|
Use of complementary and alternative medicine among women with gynecologic cancers.
|
Gynecol Oncol
|
2002
|
1.72
|
18
|
Cervical carcinoma in the elderly: an analysis of patterns of care and outcome.
|
Cancer
|
2005
|
1.68
|
19
|
Defining the limits of radical cytoreductive surgery for ovarian cancer.
|
Gynecol Oncol
|
2011
|
1.66
|
20
|
Management of symptomatic ascites in recurrent ovarian cancer patients using an intra-abdominal semi-permanent catheter.
|
Am J Hosp Palliat Care
|
2002
|
1.65
|
21
|
Effect of surgical volume on outcomes for laparoscopic hysterectomy for benign indications.
|
Obstet Gynecol
|
2012
|
1.58
|
22
|
Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history.
|
Am J Hum Genet
|
2004
|
1.57
|
23
|
Regionalization of care for obstetric hemorrhage and its effect on maternal mortality.
|
Obstet Gynecol
|
2010
|
1.56
|
24
|
The effect of surgeon volume on outcomes and resource use for vaginal hysterectomy.
|
Obstet Gynecol
|
2010
|
1.56
|
25
|
Scientific evidence underlying the American College of Obstetricians and Gynecologists' practice bulletins.
|
Obstet Gynecol
|
2011
|
1.55
|
26
|
Trends in surgical mesh use for pelvic organ prolapse from 2000 to 2010.
|
Obstet Gynecol
|
2012
|
1.55
|
27
|
A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer.
|
Gynecol Oncol
|
2013
|
1.54
|
28
|
Contemporary management of endometrial cancer.
|
Lancet
|
2012
|
1.51
|
29
|
Variation in ovarian conservation in women undergoing hysterectomy for benign indications.
|
Obstet Gynecol
|
2013
|
1.46
|
30
|
Postpartum sterilization: small incision, big complication.
|
Obstet Gynecol
|
2008
|
1.40
|
31
|
Lack of benefit of concurrent chemotherapy in patients with cervical cancer and negative lymph nodes by FDG-PET.
|
Int J Radiat Oncol Biol Phys
|
2005
|
1.39
|
32
|
Frequent HOXA11 and THBS2 promoter methylation, and a methylator phenotype in endometrial adenocarcinoma.
|
Clin Cancer Res
|
2003
|
1.36
|
33
|
SGO White Paper on ovarian cancer: etiology, screening and surveillance.
|
Gynecol Oncol
|
2010
|
1.27
|
34
|
Fertility preservation in young women with epithelial ovarian cancer.
|
Cancer
|
2009
|
1.24
|
35
|
Quality of perioperative venous thromboembolism prophylaxis in gynecologic surgery.
|
Obstet Gynecol
|
2011
|
1.21
|
36
|
Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-D-glucose-positron emission tomography.
|
Cancer
|
2005
|
1.20
|
37
|
The utility of preoperative endometrial sampling for the detection of uterine sarcomas.
|
Gynecol Oncol
|
2008
|
1.17
|
38
|
Natural history and outcome of mucinous carcinoma of the ovary.
|
Am J Obstet Gynecol
|
2011
|
1.16
|
39
|
Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer.
|
Gynecol Oncol
|
2004
|
1.15
|
40
|
Effect of surgical volume on morbidity and mortality of abdominal hysterectomy for endometrial cancer.
|
Obstet Gynecol
|
2011
|
1.14
|
41
|
Failure to rescue as a source of variation in hospital mortality for ovarian cancer.
|
J Clin Oncol
|
2012
|
1.14
|
42
|
Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their effect on outcomes.
|
JAMA Intern Med
|
2013
|
1.13
|
43
|
MSI in endometrial carcinoma: absence of MLH1 promoter methylation is associated with increased familial risk for cancers.
|
Int J Cancer
|
2002
|
1.12
|
44
|
Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behavior.
|
Obstet Gynecol
|
2008
|
1.12
|
45
|
The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma.
|
Am J Obstet Gynecol
|
2008
|
1.12
|
46
|
Occult supraclavicular lymph node metastasis identified by FDG-PET in patients with carcinoma of the uterine cervix.
|
Gynecol Oncol
|
2003
|
1.10
|
47
|
Effect of radical cytoreductive surgery on omission and delay of chemotherapy for advanced-stage ovarian cancer.
|
Obstet Gynecol
|
2012
|
1.09
|
48
|
Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer.
|
Cancer
|
2014
|
1.08
|
49
|
The evolution of cost-effective screening and prevention of cervical carcinoma: implications of the 2006 consensus guidelines and human papillomavirus vaccination.
|
Am J Obstet Gynecol
|
2007
|
1.05
|
50
|
Safety of ovarian preservation in premenopausal women with endometrial cancer.
|
J Clin Oncol
|
2009
|
1.04
|
51
|
Carcinosarcoma of the ovary: natural history, patterns of treatment, and outcome.
|
Gynecol Oncol
|
2013
|
1.03
|
52
|
Use of guideline-based antibiotic prophylaxis in women undergoing gynecologic surgery.
|
Obstet Gynecol
|
2013
|
1.03
|
53
|
Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group.
|
J Clin Oncol
|
2003
|
1.03
|
54
|
Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone.
|
Gynecol Oncol
|
2012
|
1.02
|
55
|
CD83 gene polymorphisms increase susceptibility to human invasive cervical cancer.
|
Cancer Res
|
2007
|
1.01
|
56
|
Feasibility and economic impact of same-day discharge for women who undergo laparoscopic hysterectomy.
|
Am J Obstet Gynecol
|
2012
|
1.01
|
57
|
A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer.
|
Gynecol Oncol
|
2007
|
1.00
|
58
|
The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study.
|
Gynecol Oncol
|
2009
|
1.00
|
59
|
Therapeutic role of lymphadenectomy for cervical cancer.
|
Cancer
|
2010
|
1.00
|
60
|
Sarcoma of the cervix: natural history and outcomes.
|
Gynecol Oncol
|
2010
|
1.00
|
61
|
Morbidity and mortality of peripartum hysterectomy.
|
Obstet Gynecol
|
2010
|
1.00
|
62
|
Patterns of care and treatment outcomes for elderly women with cervical cancer.
|
Cancer
|
2011
|
1.00
|
63
|
ASTEC lymphadenectomy and radiation therapy studies: are conclusions valid?
|
Gynecol Oncol
|
2009
|
0.98
|
64
|
Three cases of hemolytic uremic syndrome in ovarian cancer patients treated with combination gemcitabine and pegylated liposomal doxorubicin.
|
Gynecol Oncol
|
2005
|
0.98
|
65
|
The commercialization of robotic surgery: unsubstantiated marketing of gynecologic surgery by hospitals.
|
Am J Obstet Gynecol
|
2012
|
0.97
|
66
|
The significance of pneumatosis intestinalis or bowel perforation in patients with gynecologic malignancies.
|
Gynecol Oncol
|
2002
|
0.96
|
67
|
Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer.
|
Gynecol Oncol
|
2002
|
0.96
|
68
|
Influence of surgical volume on outcome for laparoscopic hysterectomy for endometrial cancer.
|
Ann Surg Oncol
|
2011
|
0.96
|
69
|
Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis.
|
Eur J Cancer
|
2012
|
0.95
|
70
|
Fertility-conserving surgery for young women with stage IA1 cervical cancer: safety and access.
|
Obstet Gynecol
|
2010
|
0.95
|
71
|
Natural history of established low grade cervical intraepithelial (CIN 1) lesions.
|
Anticancer Res
|
2008
|
0.94
|
72
|
Adherence to evidence-based guidelines for preoperative testing in women undergoing gynecologic surgery.
|
Obstet Gynecol
|
2010
|
0.94
|
73
|
Human papillomavirus type and tobacco use as predictors of survival in early stage cervical carcinoma.
|
Gynecol Oncol
|
2005
|
0.94
|
74
|
The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
|
Gynecol Oncol
|
2004
|
0.94
|
75
|
Uptake and outcomes of intensity-modulated radiation therapy for uterine cancer.
|
Gynecol Oncol
|
2013
|
0.94
|
76
|
Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
|
Gynecol Oncol
|
2004
|
0.94
|
77
|
Endometrial cancer in the oldest old: Tumor characteristics, patterns of care, and outcome.
|
Gynecol Oncol
|
2011
|
0.93
|
78
|
The influence of surgical volume on morbidity and mortality of radical hysterectomy for cervical cancer.
|
Am J Obstet Gynecol
|
2011
|
0.93
|
79
|
Improved survival for fallopian tube cancer: a comparison of clinical characteristics and outcome for primary fallopian tube and ovarian cancer.
|
Cancer
|
2008
|
0.93
|
80
|
Quality of venous thromboembolism prophylaxis in patients undergoing oncologic surgery.
|
Ann Surg
|
2011
|
0.93
|
81
|
Venous thromboembolism and use of prophylaxis among women undergoing laparoscopic hysterectomy.
|
Obstet Gynecol
|
2011
|
0.92
|
82
|
Comparative effectiveness of minimally invasive and abdominal radical hysterectomy for cervical cancer.
|
Gynecol Oncol
|
2012
|
0.92
|
83
|
Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study.
|
Gynecol Oncol
|
2008
|
0.92
|
84
|
A review of the current evidence for maintenance therapy in ovarian cancer.
|
Gynecol Oncol
|
2009
|
0.92
|
85
|
Long-term outcome and natural history of uterine adenosarcomas.
|
Gynecol Oncol
|
2010
|
0.91
|
86
|
Morbidity of cytoreductive surgery in the elderly.
|
Am J Obstet Gynecol
|
2004
|
0.91
|
87
|
Bevacizumab in treatment of high-risk ovarian cancer--a cost-effectiveness analysis.
|
Oncologist
|
2014
|
0.91
|
88
|
Ribosomal DNA methylation in patients with endometrial carcinoma: an independent prognostic marker.
|
Cancer
|
2002
|
0.90
|
89
|
Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma.
|
Expert Rev Anticancer Ther
|
2008
|
0.90
|
90
|
Age considerations when vaccinating against HPV.
|
Gynecol Oncol
|
2008
|
0.90
|
91
|
Follicular stimulating hormone enhances Notch 1 expression in SK-OV-3 ovarian cancer cells.
|
J Gynecol Oncol
|
2010
|
0.90
|
92
|
FDG-PET lymph node staging and survival of patients with FIGO stage IIIb cervical carcinoma.
|
Int J Radiat Oncol Biol Phys
|
2003
|
0.89
|
93
|
Pelvic radiotherapy and the risk of secondary leukemia and multiple myeloma.
|
Cancer
|
2010
|
0.89
|
94
|
Targeted therapies in epithelial ovarian cancer.
|
J Oncol
|
2010
|
0.89
|
95
|
The impact of cervical cancer on quality of life: a personal account.
|
Gynecol Oncol
|
2008
|
0.89
|
96
|
Patterns of use of hemostatic agents in patients undergoing major surgery.
|
J Surg Res
|
2013
|
0.88
|
97
|
Acceptance and compliance with postpartum human papillomavirus vaccination.
|
Obstet Gynecol
|
2012
|
0.88
|
98
|
Qualitative Evaluation of Medical Information Processing Needs of 60 Women Choosing Ovarian Cancer Surveillance or Prophylactic Oophorectomy.
|
J Genet Couns
|
2002
|
0.88
|
99
|
Synchronous ovarian metastases at the time of laparotomy for colon cancer.
|
Gynecol Oncol
|
2004
|
0.87
|
100
|
Contemporary clinical management of endometrial cancer.
|
Obstet Gynecol Int
|
2013
|
0.86
|
101
|
Increased risk for hereditary nonpolyposis colorectal cancer-associated synchronous and metachronous malignancies in patients with microsatellite instability-positive endometrial carcinoma lacking MLH1 promoter methylation.
|
Clin Cancer Res
|
2004
|
0.86
|
102
|
Morbidity and mortality of surgery for endometrial cancer in the oldest old.
|
Am J Obstet Gynecol
|
2011
|
0.86
|
103
|
Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study.
|
Int J Gynecol Cancer
|
2014
|
0.86
|
104
|
The utility and cost effectiveness of preoperative computed tomography for patients with uterine malignancies.
|
Gynecol Oncol
|
2008
|
0.85
|
105
|
An economic analysis of robotically assisted hysterectomy.
|
Obstet Gynecol
|
2014
|
0.85
|
106
|
Investigational agents in development for the treatment of ovarian cancer.
|
Invest New Drugs
|
2012
|
0.85
|
107
|
Assessing the adequacy of surgical staging for ovarian cancer.
|
Gynecol Oncol
|
2006
|
0.84
|
108
|
Long-term semi-permanent catheter use for the palliation of malignant ascites.
|
Gynecol Oncol
|
2006
|
0.84
|
109
|
What is the role of HPV typing in the United States now and in the next five years in a vaccinated population?
|
Gynecol Oncol
|
2010
|
0.84
|
110
|
Amplification of the chromosome 3q26 region shows high negative predictive value for nonmalignant transformation of LSIL cytologic finding.
|
Am J Obstet Gynecol
|
2010
|
0.84
|
111
|
Stable suppression of MDR-1 gene using siRNA expression vector to reverse drug resistance in a human uterine sarcoma cell line.
|
Gynecol Oncol
|
2005
|
0.84
|
112
|
Optimizing the management of stage II endometrial cancer: the role of radical hysterectomy and radiation.
|
Am J Obstet Gynecol
|
2009
|
0.84
|
113
|
Recurrent vulvar carcinoma in pregnancy.
|
Gynecol Oncol
|
2004
|
0.83
|
114
|
Novel cytotoxic agents from an unexpected source: bile acids and ovarian tumor apoptosis.
|
Gynecol Oncol
|
2007
|
0.83
|
115
|
Placental site trophoblastic tumor presenting with a pneumothorax during pregnancy.
|
Obstet Gynecol
|
2002
|
0.83
|
116
|
A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference?
|
Gynecol Oncol
|
2004
|
0.83
|
117
|
Unmet needs in ovarian cancer: dividing histologic subtypes to exploit novel targets and pathways.
|
Curr Cancer Drug Targets
|
2013
|
0.82
|
118
|
Cervical cancer prevention in the era of prophylactic vaccines: a preview for gynecologic oncologists.
|
Gynecol Oncol
|
2006
|
0.82
|
119
|
Microinvasive adenocarcinoma of the cervix.
|
Am J Obstet Gynecol
|
2011
|
0.82
|
120
|
Neoadjuvant bevacizumab in a granulosa cell tumor of the ovary: a case report.
|
Anticancer Res
|
2010
|
0.81
|
121
|
Stage IIIA endometrial carcinoma: outcome and predictors of survival.
|
Obstet Gynecol
|
2009
|
0.81
|
122
|
Surgical and systemic management of endometrial cancer: an international survey.
|
Arch Gynecol Obstet
|
2014
|
0.81
|
123
|
Epithelial ovarian tumors of low malignant potential: the role of microinvasion.
|
Obstet Gynecol
|
2002
|
0.81
|
124
|
Risk and predictors of malignancy in women with endometrial polyps.
|
Ann Surg Oncol
|
2011
|
0.81
|
125
|
Failure to rescue after major gynecologic surgery.
|
Am J Obstet Gynecol
|
2013
|
0.81
|
126
|
Comparison of the prognostic significance of uterine factors and nodal status for endometrial cancer.
|
Am J Obstet Gynecol
|
2011
|
0.80
|
127
|
Patterns of care for locally advanced vulvar cancer.
|
Am J Obstet Gynecol
|
2013
|
0.80
|
128
|
Current treatment strategies for endometrial cancer.
|
Expert Rev Anticancer Ther
|
2008
|
0.80
|
129
|
What is the clinical value of adding tamoxifen to progestins in the treatment [correction for treament] of advanced or recurrent endometrial cancer?
|
Gynecol Oncol
|
2004
|
0.80
|
130
|
Emerging therapies: angiogenesis inhibitors for ovarian cancer.
|
Expert Opin Emerg Drugs
|
2015
|
0.80
|
131
|
Prognostic significance and treatment implications of positive peritoneal cytology in endometrial adenocarcinoma: Unraveling a mystery.
|
Gynecol Oncol
|
2009
|
0.79
|
132
|
Liquid-based cytology for the postirradiation surveillance of women with gynecologic malignancies.
|
Gynecol Oncol
|
2003
|
0.79
|
133
|
Pharmacotherapy of endometrial cancer.
|
Expert Opin Pharmacother
|
2009
|
0.79
|
134
|
CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan.
|
Gynecol Oncol
|
2006
|
0.79
|
135
|
Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies.
|
Cancer
|
2003
|
0.79
|
136
|
Prognostic significance of mucinous differentiation of endometrioid adenocarcinoma of the endometrium.
|
Cancer Invest
|
2013
|
0.79
|
137
|
Paclitaxel poliglumex for ovarian cancer.
|
Expert Opin Investig Drugs
|
2011
|
0.78
|
138
|
Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients.
|
Oncologist
|
2007
|
0.78
|
139
|
Carboplatin-gemcitabine in the therapy of advanced ovarian cancer: dose reduction consideration.
|
J Oncol Pharm Pract
|
2009
|
0.77
|
140
|
Biologic therapies and personalized medicine in gynecologic malignancies.
|
Obstet Gynecol Clin North Am
|
2012
|
0.77
|
141
|
The role of heated intraperitoneal chemotherapy (HIPEC) in ovarian cancer: hope or hoax?
|
Ann Surg Oncol
|
2012
|
0.77
|
142
|
Utilization and safety of sodium hyaluronate-carboxymethylcellulose adhesion barrier.
|
Dis Colon Rectum
|
2013
|
0.77
|
143
|
Utility and cost-effectiveness of preoperative autologous blood donation in gynecologic and gynecologic oncology patients.
|
Obstet Gynecol
|
2002
|
0.76
|
144
|
Human papillomavirus: emerging trends in detection and management.
|
Curr Womens Health Rep
|
2002
|
0.76
|
145
|
Relationship of ovarian neoplasms and body mass index.
|
J Reprod Med
|
2005
|
0.76
|
146
|
The role of Notch and gamma-secretase inhibition in an ovarian cancer model.
|
Anticancer Res
|
2013
|
0.76
|
147
|
The new era of cervical cancer prevention: HPV vaccination.
|
Gynecol Oncol
|
2008
|
0.76
|
148
|
Enhancing the needle count in the haystack: serial ultrasonography for low-to-moderate risk adnexal masses.
|
Obstet Gynecol
|
2013
|
0.75
|
149
|
Clear cell adenocarcinoma of the ovary associated with in utero diethylstilbestrol exposure: case report and clinical overview.
|
Medscape J Med
|
2009
|
0.75
|
150
|
Fertility sparing therapy for ovarian cancer has inherent risks and benefits.
|
Arch Gynecol Obstet
|
2005
|
0.75
|
151
|
Early metastatic spread after a complete response in locally advanced vulvar cancer treated with neoadjuvant chemoradiation: a case report.
|
J Reprod Med
|
2008
|
0.75
|
152
|
Practice patterns and knowledge of obstetricians and gynecologists regarding placenta accreta.
|
J Matern Fetal Neonatal Med
|
2013
|
0.75
|
153
|
Evolution of Chemosensitivity and Resistance Assays as Predictors of Clinical Outcomes in Epithelial Ovarian Cancer Patients.
|
Curr Pharm Des
|
2016
|
0.75
|
154
|
Detection and significance of parametrial micrometastases in early-stage cervical cancer.
|
Anticancer Res
|
2011
|
0.75
|
155
|
Hemolytic uremic syndrome presenting after treatment of endodermal sinus tumor.
|
Obstet Gynecol
|
2004
|
0.75
|
156
|
Access to conservative surgical therapy for adolescents with benign ovarian masses.
|
Obstet Gynecol
|
2012
|
0.75
|
157
|
Unintended consequences: surgical complications in gynecologic cancer.
|
Womens Health (Lond Engl)
|
2013
|
0.75
|
158
|
Safety of conservative management of ovarian masses during pregnancy.
|
J Reprod Med
|
2013
|
0.75
|
159
|
Panniculectomy: improving lymph node yield in morbidly obese patients with endometrial neoplasms.
|
Gynecol Oncol
|
2004
|
0.75
|
160
|
Supporting gynecologic cancer research: the last 20 years and beyond.
|
Gynecol Oncol
|
2011
|
0.75
|